Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Harmonized 25(OH)D data were obtained from the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, including 79,570 participants examined between 1984 and 2010.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A total of 79,570 participants were eligible for cross-sectional analyses ().

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Cardiovascular disease outcomes in relation to 25-hydroxyvitamin D and its seasonal variation: Results from the BiomarCaRE consortium

Study design awaiting verification · PLOS One · 2025

Original publication title

Cardiovascular disease outcomes in relation to 25-hydroxyvitamin D and its seasonal variation: Results from the BiomarCaRE consortium

Viktor Oskarsson; Veikko Salomaa; Pekka Jousilahti; Luigi Palmieri; Chiara Donfrancesco; Susana Sans; Licia Iacoviello; Simona Costanzo; Marco M. Ferrario; Giancarlo Cesana; Barbara Thorand; Annette Peters; Hugh Tunstall-Pedoe; Mark Woodward; Tanja Zeller; Stefan Blankenberg; Kari Kuulasmaa; Stefan Söderberg

© 2025 Oskarsson et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The present study does not support the hypothesis that seasonal increases in CVD are driven by short-term reductions in 25(OH)D. As in most observational studies, higher 25(OH)D concentrations were inversely associated with CVD.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

It has been hypothesized but seldom tested that the winter excess in cardiovascular disease (CVD) is related to hypovitaminosis D. The present study examined the association between CVD and (i) seasonality of 25-hydroxyvitamin D (25[OH]D) and (ii) individual 25(OH)D concentrations.

Source: Background

Abstract: Methods and findings

Harmonized 25(OH)D data were obtained from the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, including 79,570 participants examined between 1984 and 2010. One 25(OH)D measurement was available per participant. Primary endpoints were CVD incidence (coronary heart disease or stroke; n = 6006) and CVD mortality (n = 2985). To study (i), Poisson regression-derived rate ratios were compared according to two-month categories, ordered by baseline 25(OH)D concentrations. To study (ii), Cox regression-derived hazard ratios were compared according to quarters of baseline 25(OH)D concentrations.

With respect to (i), despite a median 25(OH)D concentration ratio of 1:1.79, the trough months of 25(OH)D in March and April had a similar CVD incidence as the peak months of 25(OH)D in August and September (rate ratio: 1.07, 95% CI: 0.98 to 1.17). CVD mortality was slightly higher in the trough months compared to the peak months (rate ratio: 1.27, 95% CI: 1.12 to 1.44) but not compared to the other months (despite median 25[OH]D concentration ratios up to 1:1.62; p ≥ 0.077).

The CVD mortality peak in January preceded the 25(OH)D trough, not adhering to the temporality criterion of Bradford Hill. With respect to (ii), compared to the lowest quarter, the highest quarter of 25(OH)D was associated with lower CVD incidence (hazard ratio: 0.82, 95% CI: 0.76 to 0.89) and CVD mortality (hazard ratio: 0.64, 95% CI: 0.57 to 0.72).

Source: Methods and findings

Abstract: Conclusion

The present study does not support the hypothesis that seasonal increases in CVD are driven by short-term reductions in 25(OH)D. As in most observational studies, higher 25(OH)D concentrations were inversely associated with CVD.

Source: Conclusion
Authors’ abstract

Background

It has been hypothesized but seldom tested that the winter excess in cardiovascular disease (CVD) is related to hypovitaminosis D. The present study examined the association between CVD and (i) seasonality of 25-hydroxyvitamin D (25[OH]D) and (ii) individual 25(OH)D concentrations.

Methods and findings

Harmonized 25(OH)D data were obtained from the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, including 79,570 participants examined between 1984 and 2010. One 25(OH)D measurement was available per participant. Primary endpoints were CVD incidence (coronary heart disease or stroke; n = 6006) and CVD mortality (n = 2985). To study (i), Poisson regression-derived rate ratios were compared according to two-month categories, ordered by baseline 25(OH)D concentrations. To study (ii), Cox regression-derived hazard ratios were compared according to quarters of baseline 25(OH)D concentrations.

With respect to (i), despite a median 25(OH)D concentration ratio of 1:1.79, the trough months of 25(OH)D in March and April had a similar CVD incidence as the peak months of 25(OH)D in August and September (rate ratio: 1.07, 95% CI: 0.98 to 1.17). CVD mortality was slightly higher in the trough months compared to the peak months (rate ratio: 1.27, 95% CI: 1.12 to 1.44) but not compared to the other months (despite median 25[OH]D concentration ratios up to 1:1.62; p ≥ 0.077).

The CVD mortality peak in January preceded the 25(OH)D trough, not adhering to the temporality criterion of Bradford Hill. With respect to (ii), compared to the lowest quarter, the highest quarter of 25(OH)D was associated with lower CVD incidence (hazard ratio: 0.82, 95% CI: 0.76 to 0.89) and CVD mortality (hazard ratio: 0.64, 95% CI: 0.57 to 0.72).

Conclusion

The present study does not support the hypothesis that seasonal increases in CVD are driven by short-term reductions in 25(OH)D. As in most observational studies, higher 25(OH)D concentrations were inversely associated with CVD.

Publication and source details

Original title: Cardiovascular disease outcomes in relation to 25-hydroxyvitamin D and its seasonal variation: Results from the BiomarCaRE consortium

Viktor Oskarsson; Veikko Salomaa; Pekka Jousilahti; Luigi Palmieri; Chiara Donfrancesco; Susana Sans; Licia Iacoviello; Simona Costanzo; Marco M. Ferrario; Giancarlo Cesana; Barbara Thorand; Annette Peters; Hugh Tunstall-Pedoe; Mark Woodward; Tanja Zeller; Stefan Blankenberg; Kari Kuulasmaa; Stefan Söderberg

PLOS One · 2025

* E-mail: viktor.oskarsson@umu.se

Competing Interests: Abbott Diagnostics provided test reagents for the 25(OH)D measurements within the frame of the BiomarCaRE project. Abbott Diagnostics had no role in the study design, data collection, blood sample and data analysis, decision to publish, or preparation of the manuscript. Veikko Salomaa has received an honorarium from Sanofi for consulting and has ongoing research collaboration with Bayer Ltd (both outside of the submitted work). Mark Woodward has done consultancy work for Amgen and Freeline (outside of the submitted work).

Stefan Blankenberg has recieved research funding from Abbott Diagnostics, Bayer, SIEMENS, Singulex, and Thermo Fisher; speaker fees from Abbott, Abbott Diagnostics, Astra Zeneca, Bayer, AMGEN, Medtronic, Pfizer, Roche, SIEMENS Diagnostics, SIEMENS, and Thermo Fisher; and honoraria as a member of advisory boards and for consulting for Bayer, Novartis, and Thermo Fisher (all outside of the submitted work). Stefan Söderberg has recieved speaker fees and done consultancy work for Merck Sharp & Dohme and Actelion Pharmaceuticals Ltd, a Johnson & Johnson company (both outside of the submitted work).

This does not alter our adherence to PLOS ONE policies on sharing data and materials.

© 2025 Oskarsson et al2025Oskarsson et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.EU project MORGAM Biomed, BMH4-CT98-3183EU project GenomEUtwin FP5, QLG2-CT-2002-01254EU project ENGAGE FP7, HEALTH-F4-2007-201413EU project CHANCES FP7, HEALTH-F3-2010-242244EU project BiomarCaRE FP7, HEALTH-F2-2011-278913EU project euCanSHare Horizon 2020, No. 825903EU project AFFECT-EU Horizon 2020, No. 847770 http://dx.doi.org/10.13039/501100000265Medical Research Council G0601463, No. 80983: Biomarkers in the MORGAM Populations http://dx.doi.org/10.13039/501100013295Helmholtz Zentrum München Ludwig-Maximilians-Universität Catalan Department of Health Scottish Health Department Chief Scientist Office http://dx.doi.org/10.13039/501100000274British Heart Foundation FP Fleming Trust http://dx.doi.org/10.13039/501100009882Regione Lombardia http://dx.doi.org/10.13039/501100009772Norrbottens Läns Landsting https://orcid.org/0000-0002-2936-2895 Oskarsson Viktor Piteå Älvdals Hospital Foundation https://orcid.org/0000-0002-2936-2895 Oskarsson Viktor Norrländska Hjärtfonden https://orcid.org/0000-0002-2936-2895 Oskarsson Viktor http://dx.doi.org/10.13039/501100002960Västerbotten Läns Landsting https://orcid.org/0000-0001-9225-1306 Söderberg Stefan http://dx.doi.org/10.13039/501100004885Umeå Universitet https://orcid.org/0000-0001-9225-1306 Söderberg Stefan Joint Committee of County Councils in northern Sweden https://orcid.org/0000-0001-9225-1306 Söderberg Stefan Finnish Foundation for Cardiovascular Research https://orcid.org/0000-0001-7563-5324 Salomaa Veikko Juho Vainio Foundation https://orcid.org/0000-0001-7563-5324 Salomaa Veikko German Centre for Cardiovascular Research Zeller Tanja The MORGAM/BiomarCaRE project has received funding from EU projects MORGAM (Biomed, BMH4-CT98-3183), GenomEUtwin (FP5, QLG2-CT-2002-01254), ENGAGE (FP7, HEALTH-F4-2007-201413), CHANCES (FP7, HEALTH-F3-2010-242244), BiomarCaRE (FP7, HEALTH-F2-2011-278913), euCanSHare (Horizon 2020, No. 825903), and AFFECT-EU (Horizon 2020, No. 847770) as well as from Medical Research Council, London (G0601463, No. 80983: Biomarkers in the MORGAM Populations). This has supported central coordination, workshops, and part of the activities of the MORGAM Data Centre, the MORGAM Laboratories, and the MORGAM Participating Centres. The KORA study was initiated and financed by the Helmholtz Zentrum München and also supported within the Munich Center of Health Sciences, Ludwig-Maximilians-Universität, as part of the LMUinnovativ. The MORGAM/MONICA-Catalonia study was financed by the former Institute of Health Studies, Department of Health and Social Security, Generalitat of Catalunya, and with logistic support from the Hospital de la Santa Creu i Sant Pau, Barcelona. The SHHEC study was financed by the Scottish Health Department Chief Scientist Office, the British Heart Foundation, and the FP Fleming Trust. The MONICA Brianza study was mainly supported by the Health Administration of Regione Lombardia. Viktor Oskarsson and Stefan Söderberg were supported by grants from (1) the County Councils of Norrbotten and Västerbotten, (2) the Piteå Älvdals Hospital Foundation, (3) Norrländska Hjärtfonden, (4) the Joint Committee of County Councils in northern Sweden, and (5) Umeå University, Umeå, Sweden. Veikko Salomaa was supported by the Finnish Foundation for Cardiovascular Research and the Juho Vainio Foundation. Tanja Zeller was supported by the German Centre for Cardiovascular Research. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:08:24.044744+00:00

DOI: 10.1371/journal.pone.0319607 · PMC12021148